{
  "id": 20828622,
  "title": "Nektar Therapeutics president & CEO Howard Robin sells $15,379 in stock",
  "url": "https://urgent.news/2026/11/20/nektar-therapeutics-president-ceo-howard-robin-sells-15-379-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-20T00:15:50.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/nektar-therapeutics-president--ceo-howard-robin-sells-15379-in-stock-93CH-5040392"
  },
  "original_language": "en",
  "account": "Nektar Therapeutics' CEO, Howard Robin, sold 429 shares of the company's stock on November 17, 2026, to satisfy tax withholding requirements related to the vesting of restricted stock units. The transaction occurred as Robin's holdings were reduced to 54,198 shares, with an additional 28 shares belonging to his spouse indirectly. The shares were traded at prices between $35.57 and $36.31, with a weighted average sale price of $35.85. Following the sale, Nektar Therapeutics' stock fell to $32.54, nearing its 52-week low of $32.51 and dropping nearly 13% in a single week. Despite this, the stock is considered to be at fair value, according to InvestingPro analysis. Nektar Therapeutics reported its third-quarter financial results, posting adjusted earnings of minus $1.63 per share, surpassing analyst expectations of a minus $2.08 loss. However, revenue fell short of estimates, totaling $9.39 million compared to the projected $10.31 million. The company's substantial cash reserves, amounting to approximately $952.9 million, are anticipated to sustain its operations through the initial results of its Phase 3 ZENITH AD trials in atopic dermatitis, scheduled for 2028. Nektar's REZPEG treatment has advanced to Phase III studies for atopic dermatitis and alopecia areata. While the earnings beat was positive, investor focus shifted towards the revenue shortfall and the lengthy journey to commercialization, reflecting the typical strategy of biotechnology companies in their late-stage development.",
  "summary": null,
  "key_points": [
    "Howard Robin sold 429 Nektar Therapeutics shares for $15,379 on November 17, 2026",
    "Share price dropped to $32.54, nearing 52-week low of $32.51",
    "Nektar reported adjusted earnings of minus $1.63 per share, beating expectations"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}